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Objectives- Oxidized cholesterol metabolites are linked to increased production of the active 
vitamin A (Vit-A) form and monocyte/macrophage activation, which may be reflected by 
neopterin, a marker of both interferon-γ- mediated immune activation and coronary artery 
disease risk. We examined the influence of serum lipid parameters and Vit-A on the risk 
association between neopterin and incident acute myocardial infarction (AMI). 
Methods- We included 4130 patients with suspected stable angina pectoris (SAP), of whom 
80% received lipid-lowering treatment with statins. Risk associations between plasma 
neopterin and AMI are given as HRs per SD increase in log-transformed neopterin.  
Results- During a median follow-up of 7.5 years, 530 (12.8%) patients experienced an AMI. 
In age and sex-adjusted analysis, plasma neopterin was positively associated with incident 
AMI (HR [95% CI] per SD: 1.26 [1.17-1.35]). However, the estimates were most pronounced 
in patients with serum low-density lipoprotein-cholesterol (LDL-C) or apolipoprotein (apo) 
B100 below-median (HR [95% CI] per SD: 1.35 [1.24-1.48] and 1.42[1.27-1.58], 
respectively; both Pinteraction≤ 0.03). We also observed a particularly strong risk association in 
those with above-median Vit-A (HR [95% CI] per SD: 1.32 [1.21-1.44]; Pinteraction= 0.03). The 
estimates were slightly modified after multivariable adjustment. 
Conclusions- In patients with suspected SAP, the majority of whom receiving statin therapy, 
high plasma neopterin was associated with increased risk of AMI particularly among those 
with low LDL-C and apoB100 or high Vit-A levels. The particularly strong relationship of 
plasma neopterin with residual cardiovascular risk in patients with low lipid levels should be 
further investigated. 








What is already known on this topic 
 
 Higher plasma neopterin, an interferon-γ (IFN) - mediated immune activation marker 
is associated with increased risk of cardiovascular events  
 Evidence suggests that alterations in lipid metabolism influences cellular immune 
activation and are a major contributing factor to the development of atherosclerotic 
cardiovascular diseases. 
 On the other hand, statins, aimed at improving the lipid profile, do not eliminate 
atherosclerosis, as an incident major cardiovascular event occurs in a substantial 
proportion of patients who receive statin therapy 
What this study adds 
 Plasma neopterin was associated with increased risk of incident AMI predominantly in 
patients with high serum Vit-A and those with low serum LDL-C and apoB100 levels, 
in whom a particularly strong relationship was suggested among the majority 
receiving statin therapy. 
 
How might this impact on clinical practice? 
 
Future studies should investigate whether the risk relationship between plasma neopterin and 












Atherosclerosis is a multifactorial disease characterized by the accumulation of lipids and 
chronic inflammation in the arterial wall, and is the major cause of cardiovascular disease 
(CVD)[1]. Elevated serum low-density lipoprotein-cholesterol (LDL-C) has been established 
as a major risk factor for atherosclerotic CVD[2]. LDL-C lowering therapy with statins 
significantly reduces the risk of cardiovascular events[2] and is expected to be caused by an 
increased uptake[2] and catabolism of atherogenic lipids in the liver[3], suggesting that LDL-
C is a cause of atherosclerotic disease[2]. However, residual cardiovascular risk remains 
prevalent in a substantial proportion of patients on lipid-lowering therapy with statins[4], 
reflecting the complex pathophysiology of atherosclerotic disease. 
Neopterin is a pteridine derivative secreted from activated macrophages and a marker 
of interferon-γ (IFN) - mediated immune activity[5, 6]. Elevated circulating neopterin levels 
have been associated with adverse cardiovascular events in the subsample of the current 
cohort[6] and in patients undergoing angiography[7]as well as in healthy, elderly adults[8].  
Available evidence suggests a mutual interplay between lipid metabolism and cellular 
immune activation. More specifically, high plasma neopterin has been associated with 
reduced LDL-C and high-density lipoprotein cholesterol (HDL-C)[7]. Further, lipid-lowering 
therapy with peroxisome proliferator-activated receptor (PPAR) α agonists enhances very- 
low-density lipoprotein (VLDL) apolipoprotein (apo) B100 catabolism and reduces VLDL 
apoB100 production[9], in addition to impairing the transcription of glycine N-
methyltransferase (GNMT)[10], a critical regulator of VLDL assembly and secretion[11]. 
Notably, these disturbances are classical components of intracellular hepatic lipid 
accumulation[11, 12], characterized by the secretion of large buoyant triglyceride (TG)-rich 
but cholesterol poor lipoproteins, resulting in the formation of small-dense LDL (sdLDL) 





[13]. Oxidized lipids regulate recruitment and activation of monocytes [1, 15], and lipid 
oxidation products regulate synthesis of all-trans retinoic acid[16], an active form of vitamin-
A (Vit-A) involved in the monocyte differentiation[17]. Since monocytes/macrophages 
involved in atherosclerosis development produce neopterin in response to IFN-γ 
stimulation[5, 6], cellular cholesterol metabolism and transport in macrophages may be 
reflected in neopterin production. Of note, neopterin was recently shown to enhance 
cholesterol efflux and suppress foam-cell formation in human monocyte-derived 
macrophages, and reduce atherosclerosis development in mice[18].  
Taken together, these observations suggest that altered lipid metabolism may affect 
IFN-γ mediated cellular immune activation, and thereby possibly modulate CAD risk. We 
investigated the effect modification by serum lipid measures and Vit-A on the association 
between systemic neopterin and risk of incident acute myocardial infarction (AMI) in a large 
cohort of patients with suspected stable angina pectoris (SAP).  Since the majority of patients 
in this study population were treated with lipid-modifying statins, we also evaluated the 

















The study population has been previously described[19]. In brief, 4164 patients undergoing 
coronary angiography for suspected SAP during 2000-2004 at Haukeland or Stavanger 
University Hospitals in Western Norway were studied. Of these, 2573 were enrolled in the 
Western Norway B-vitamin intervention trial (WENBIT) (ClinicalTrials.gov Identifier: 
NCT00354081). Subjects with missing data on plasma neopterin (n=34) were excluded, 
leaving 4130 subjects eligible for the final analyses. The study was performed according to 
the Declaration of Helsinki, and was approved by the Regional Medical and Health Ethics 
committee, the Norwegian Medicines Agency and the Norwegian Data Inspectorate. All 
participants provided written informed consent. 
Baseline variables 
Information about medical history was obtained through self-administered questionnaires and 
subsequently checked against hospital records, as previously reported[19].  Smoking status 
was defined according to self-reported smoking habits and also included those who reported 
having quit smoking within <1 month prior to examination and patients with serum cotinine 
>85 nmol/L.  
 
Biochemical analyses 
Previous reports have described the collection and storage of blood samples and the 
biochemical analyses of biomarkers[6, 19]. Plasma neopterin was analyzed by high-
performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) at BEVITAL 
AS, Bergen, Norway (www.bevital.no). 





Data on study events were collected from the Cardiovascular Disease in Norway project 
(CVDNOR; https://cvdnor.b.uib.no/)[20]. The primary end point was AMI (including fatal 
and non-fatal) and classification of events have been described previously[6]. Study patients 
were followed from enrollment until experiencing an AMI or throughout 2009.  
Statistical methods 
Continuous variables are presented as medians (25th–75th percentiles) and categorical 
variables as counts (percentages). Patients’ baseline characteristics across plasma neopterin 
quartiles were tested by linear regression or logistic regression for continuous and categorical 
variables, respectively. 
 Cox proportional regression models were used to calculate hazard ratios (HRs) and 
95% confidence intervals (95% CIs) for incident AMI for plasma neopterin. HRs were 
reported according to per 1 standard deviation (SD) increment in log-transformed plasma 
neopterin. The simple survival model (Model 1) was adjusted for age (continuous) and sex. 
Additional covariates in the multivariable model (Model 2) included body mass index 
(continuous), current smoking (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), 
statin treatment (yes/no), apoA1 and apoB100 (both continuous). We additionally included 
prior AMI in an extended model. Further adjustments for B-vitamin treatment, eGFR, serum 
albumin or CRP had minimal influence on the results and were excluded in the final model 
(data not shown). Proportionality assumptions were evaluated by assessing the schoenfeld 
residuals. 
 
 Serum lipid parameters and Vit-A were categorized according to their median values 
and the effect modifications with plasma neopterin were tested by including interaction 





LDL-C or apoB100 or Vit-A was estimated using the Kaplan-Meier method and compared by 
the log-rank test. Potential nonlinear-interrelationships between plasma neopterin, serum 
LDL-C or apoB100 levels, and incident AMI was explored visually by plotting generalized 
additive models, adjusted for age and sex, and surface spline plots from the unadjusted 
hazards model.  
All P values were 2-tailed, and considered significant when <0.05. Statistical analyses were 
performed using SPSS (version 23 SPSS Inc, IBM, NY, USA) and R (version 3.1.2 R Core 
Team, Vienna, Austria) 
Patient and public involvement 
The current study was conducted without patient involvement. Study patients were not 
involved in research design, the outcome measures, data analysis, result interpretation or the 
writing of this manuscript. However, we do have plans to disseminate the results of the 















Baseline characteristics  
The median (25th-75th percentile) age was 62 (55–70) years, and 72% were men. 
Median (25th–75th percentile) plasma neopterin, LDL-C, apoB100 and Vit-A were 8.2 (6.7–
10.4) nmol/L, 2.90 (2.4–3.7) mmol/L, 0.87 (0.73–1.04) g/L and 2.82 (2.5–3.3) μmol/L, 
respectively. As presented in Table 1, a higher proportion of patients in the upper neopterin 
quartile were older, women, had hypertension, diabetes mellitus or established coronary heart 
disease. We also observed positive associations of neopterin with CRP, Vit-A and high-
sensitivity troponin-T, whereas there were inverse associations with eGFR, serum albumin, as 
well as with current smoking. Plasma neopterin was also negatively associated with serum 
total cholesterol and LDL-C/apoB100 ratio, whereas no pronounced associations were 
observed with levels of LDL-C, apoB100, HDL-C, or apoA1. Furthermore, patients with 
higher neopterin levels were less likely to use statins, but were more frequently prescribed β-






Table 1. Baseline characteristics of the study population according to quartiles of plasma neopterin among patients with stable angina 
pectoris 
                                     Quartiles of plasma neopterin   
 
 










  Ptrend 
 Age, y  4130 62 (55-70)  58 (51-64)  60 (54-66)  63(56-70)  69 (60-75)  <0.001 
 Male sex, n (%)  4130 2969 (71.9)  826 (80.0)  774 (74.9)  721 (69.8)  648 (62.8)  0.001 
BMI, kg/m2  4127 26 (24-28)  26 (24-29)  26 (24-28)  26 (23-28)  26 (23-28)  0.002 
eGFR, mL/min per 1.73m2  4129 91 (78-99)  98 (91-105)  94 (86-101)  88 (77-97)  76 (62-89)  <0.001 
Serum CRP, mg/L  4128 1.78 (0.87-3.68)  1.45 (0.78-2.69)  1.67(0.78-3.23)  1.79 (0.90-3.67)  2.44 (1.16-5.41)  <0.001 
Vit-A, μmol/L  4090 2.82 (2.5-3.3)  2.73 (2.4-3.2)  2.79 (2.4-3.2)  2.84 (2.5-3.3)  2.93 (2.5-3.5)  <0.001 
TnT  4044 4.0 (3.0-10.0)   3.0 (3.0-7.0)  3.0 (3.0-8.0)  5.0 (3.0-10.0)  8.0 (3.0-17.0)  <0.001 
Serum albumin, g/L  3660 43 (41-45)  43 (42-45)  43 (42-45)  43(42-45)  42 (41-44)  <0.001 
 Coronary risk factor, n (%)              
  Hypertension  4130 1932 (46.8)  442 (42.8)  440 (42.6)  466 (45.1)  584 (56.6)  <0.001 
  Diabetes mellitus   4130 1589 (38.5)  385 (37.3)  373 (36.1)  385 (37.3)  446 (43.2)  0.002 
  Current smoking  4130 1311 (31.7)  437 (42.3)  349 (33.8)  286 (27.7)  239  (23.2)  <0.001 
 Prior AMI, n (%)  4130 1665 (40.3)  410 (39.7)  408 (39.5)  387 (37.5)  460 (44.6)  <0.001 
 LVEF (%)  4130 65 (60-70)  69 (60-70)  66 (60-70)  65 (60-70)  65 (56-70)  <0.001 
Extent of CAD, n (%)    4130           <0.001 
   No significant stenosis   1040 (25.2)  267 (25.9)  254 (24.6)  274 (26.5)  245 (23.7)   
 1-vessel disease   953 (23.1)  260 (25.2)  259 (25.1)  229 (22.2)  205 (19.9)   
 2-vessel disease   923 (22.3)  237 (23.0)  227 (22.0)  234 (22.7)  225 (21.8)   
 3-vessel disease   1214 (29.4)  268 (26.0)  293 (28.4)  296 (28.7)  357 (34.6)   















 Total cholesterol, mmol/L  4128 4.9 (4.3-5.7)  5.0 (4.3-5.8)  4.90 (4.3-5.7)  5.0 (4.3-5.7)  4.80 (4.2-5.7)  0.03 
  LDL-C, mmol/L  4126 2.90 (2.4-3.7)  2.97 (2.4-3.7)  2.91 (2.4-3.7)  2.95 (2.4-3.7)  2.90 (2.3-3.7)  0.19 
 ApoB100, g/L  4129  0.87 (0.73-1.04)  0.87 (0.74-1.05)  0.86 (0.74-1.03)  0.86 (0.72-1.04)  0.87 (0.73-1.05)  0.94 
HDL-C, mmol/L  4129 1.20 (1.0-1.50)  1.20 (1.0-1.5)  1.20 (1.0-1.5)  1.30 (1.1-1.5)  1.20 (1.0-1.5)  0.48 
Apo A1, g/L  4128 1.30 (1.13-1.48)  1.30 (1.14-1.47)  1.31(1.14-1.47)  1.31(1.14-1.51)  1.27(1.11-1.47)  0.86 
 LDL-C/ApoB100,mmol/g  4125 3.41 (3.10-3.72)  3.45 (3.16-3.75)  3.43(3.13-3.74)  3.40 (3.10-3.71)  3.37 (3.04-3.68)  0.005 
Medications at discharge, n 
(%) 
             
 Statin   4119 3313 (80.4)  836 (81.0)  857 (83.0)  812 (78.6)  803 (77.8)  0.01 
 β-Blocker  4130 2993 (72.5)  739 (71.6)  752 (72.8)  720 (69.7)  782 (75.8)  0.02 
 ACEIs and/or ARB  4130 1318 (31.9)  279 (27.3)  288 (27.9)  329 (31.8)  422 (40.9)  <0.001 
Continuous variables are presented as medians (25th–75th percentiles) and categorical variables as numbers (percentages). ACEI indicates 
angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ApoA1, apolipoprotein A1; ApoB100, apolipoprotein B100; ARB, 
angiotensin receptor blocker; BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; Tnt, Troponin T; Vit-A, Vitamin A 
measured as serum retinol.  





Plasma neopterin and incident AMI  
530 (12.8%) patients experienced an AMI during a median (25th-75th percentile) 
follow-up time of 7.5 (6.3-8.7) years. Plasma neopterin was associated with increased risk of 
AMI in age and sex-adjusted model (HR [95% CI] per 1-SD:1.26 [1.17-1.35]; P <0.001) 
(Table 2 and Supplemental Figure 1). Multivariate adjustment (Table 2) or including prior 










The neopterin-AMI risk association according to serum lipid parameters and Vit-A 
Table 3 depicts risk estimates between plasma neopterin and AMI according to the 
subgroups of serum lipids and Vit-A. Among patients with below-median LDL-C levels, 
plasma neopterin showed a linear positive association with incident AMI (HR [95% CI] per 
SD:1.35 [1.24-1.48]; P<0.001), whereas no significant risk relationship was found among 
those with above-median LDL-C (Pinteraction=0.03) (Table 3, Figure 1 and Supplemental Figure 
2). Similarly, there was a stronger relationship between plasma neopterin and AMI in patients 
Table 2. Risk association between plasma neopterin and incident acute 
myocardial infarction  
 
HR (95% CI )* 
P-value 
Unadjusted 1.33(1.25-1.42) <0.001 
Model 1† 1.26 (1.17-1.35) <0.001 
Model 2‡ 1.24 (1.15-1.33) <0.001 
Model 2 + prior AMI                1.21 (1.12-1.30) <0.001 
*Per 1-SD increase in log-transformed concentrations. 
†  Model 1 adjusted for age, and sex 
‡ Model 2 adjusted for age, sex, BMI, hypertension, diabetes mellitus , 





with below compared to above-median serum apoB100 (Table 3, Figures 2 and Supplemental 
Figure 3) (Pinteraction=0.002). We also observed a particularly strong relationship of neopterin 
in patients with serum Vit-A levels above the median (Pinteraction=0.03) (Table 3).   
Table 3. Associations between plasma neopterin (log transformed per SD) and 
AMI according to subgroups of prespecified lipid parameters and Vit-A 
Subgroups Events/Total HR (95% CI) * P-value Pint 
LDL-C†     
 ≤median 263/2075 1.35 (1.24-1.48) <0.001 0.03 
 >median 267/2051 1.11 (0.97-1.26) 0.12  
ApoB100†     
 ≤median 253/2127 1.42 (1.27-1.58) <0.001 0.002 
 >median 277/2002 1.14 (1.02-1.26) 0.02  
HDL-C†     
 ≤median 312/2123 1.19 (1.09-1.31) <0.001 0.18 
 >median 218/2006 1.36 (1.18-1.57) <0.001  
ApoA1†     
 ≤median 303/2107 1.21 (1.10-1.32) <0.001 0.20 
 >median 227/2021 1.32 (1.16-1.50) <0.001  
LDL-C/ApoB100 
ratio† 
    
 ≤median 292/2066 1.27 (1.17-1.39) <0.001 0.47 
 >median 238/2059 1.19 (1.03-1.36) 0.02  
Vit-A†     
 ≤median 267/2043 1.11 (0.97-1.28) 0.13 0.03 
 >median 254/2047 1.32 (1.21-1.44) <0.001  
AMI indicates acute myocardial infarction;  ApoA1, apolipoprotein A1; ApoB, 
apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; Vit-A, vitamin A measured a serum retinol 
*Adjusted for age and sex 
† Patients with valid measurements = 4126 (in LDL-C analyses), 4129 (ApoB100 
analyses), 4129 (HDL-C analyses), 4128 (ApoA1 analyses), 4125 (LDL-C/ApoB100 





Accordingly, reduced survival was observed in patients with a high concentration of 
neopterin but low concentration of LDL-C or apoB100 (P<0.001) (Supplemental Figures 4 
and 5). This was also the case in patients with high concentrations of both neopterin and Vit-
A (P<0.001) (Supplemental Figure 6).  The effect modification by LDL-C or apoB100 and 
Vit-A subgroups were essentially similar after multivariate adjustment (Supplemental Table 
1). The neopterin-AMI association was not significantly modified by serum HDL-C or apoA1 
(Table 3 and Supplemental Table 1). 
Notably, the neopterin-LDL-C or apoB100 risk associations were even stronger 
among patients receiving statin treatment after angiography (Supplemental Table 2 through 4) 


















In patients undergoing coronary angiography for suspected SAP, plasma neopterin predicted 
the risk of incident AMI predominantly in statin-treated patients with lower serum LDL-C or 
apoB100 concentrations, as well in patients with elevated Vit-A.  
 
Neopterin, lipid metabolism, and cardiovascular disease 
Our findings of an increased cardiovascular risk associated with higher plasma neopterin is 
concordant with previous research[6-8], including SAP[6] and may underline the importance 
of immune cell activation in the development of atherogenesis. The LDL-C hypothesis 
identifies LDL-C as a causal factor of atherosclerotic CVD [2]; however, there remains some 
uncertainty about the direct role of LDL-C [21]. On the other hand, data regarding the 
association between Vit-A and cardiac events have been contradictory[22]. To our 
knowledge, this is the first large-scale investigation to demonstrate that serum LDL-C, 
apoB100 and Vit-A concentrations modifies the association of neopterin with cardiovascular 
outcomes.  
Possible mechanisms and implications  
We observed no significant associations of plasma neopterin with serum LDL-C or apoB100 
at baseline; however, the putative associations may be masked by statin therapy, as more 
subjects in the lower neopterin quartiles were prescribed statins, which is in line with a 
previous report[7]. The activation of monocytes into macrophages accumulating intracellular 
cholesterol and other lipids in the subendothelial layer of arteries is a hallmark for 
atherosclerosis, and is also fundamental for the concept that inflammation is a promoting 
factor at all stages of atherosclerosis[1].  Here, we propose that the current findings may be 
related to the impaired hepatic VLDL production, monocyte/macrophage activation, and the 





Dysfunctional VLDL secretion has been associated with increased hepatic lipid 
accumulation[11, 12] and secretion of large VLDL particles with reduced cholesterol content, 
which leads to the formation of sdLDL particles with increased susceptibility to oxidative 
modification [12-14]. oxidized LDL activates monocytes[1, 15], and cholesterol oxidation 
products i.e oxysterols stimulate production of the active Vit-A form, all-trans retinoic acid 
[16], which again induces monocyte differentiation[17]. These findings may indicate the 
involvement of impaired hepatic apoB-containing lipoprotein secretion in 
monocytes/macrophages activation, reflected by neopterin production. Accordingly, we 
observed associations of neopterin with decreased LDL-C/apoB ratio and increased Vit-A, 
which represents the presence of sdLDL-particles[23] and modified cholesterol product[16], 
respectively. Activated monocytes take up modified LDL via the scavenger receptor, 
produces extra cholesterol and export free cholesterol to HDL-C. Notably, this export is 
regulated by ATP‐binding cassette transporter A1, which is stimulated by both neopterin[18] 
and all-trans retinoic acid [24]. Thus, oxidized LDL, increased Vit-A and neopterin 
production may primarily be a response and feed-back mechanism due to an impaired liver 
VLDL-C export, aiming to restore this deficiency of cholesterol in VLDL/LDL. Recently, in 
the same current cohort[25], we showed that that low apo A1, the primary protein constituent 
of HDL, was related to incident AMI primarily in those with high Vit-A levels. This may 
suggest that apoA1 deficiency and low HDL primarily is related to the risk of atherosclerosis 
when the endothelium produces oxidized LDL as a signal of impaired LDL-C supply. This 
hypothesis is further supported by our current observation, indicating that that the risk of AMI 
is particularly high when there are two signals of excess oxidized cholesterol production, i.e., 
the combination of elevated Vit-A and neopterin. Notably, the neopterin related risk 





strengthen the hypothesis that an impaired cholesterol supply from the liver to the 
endothelium may promote atherosclerosis. 
The mechanism responsible for reduced hepatic VLDL output is not known but could 
be related to high endogenous PPARα activity in the liver. Treatment with PPARα agonist has 
been demonstrated to increase catabolism of apoB100[9], which is a ligand for LDL-receptor-
mediated endocytosis of LDL particles, in addition to being a crucial component of VLDL 
synthesis and assembly[14]. Additionally, PPARα agonism attenuates GNMT transcription 
[10], a critical regulator of VLDL export[11]. In line with this, recent animal data suggest that 
PPARα activation may promote hepatic steatosis[26]. Notably, we observed a strong 
relationship between neopterin and AMI among patients with low LDL-C or ApoB100, and 
even more so in those treated with statins, which is suggested to stimulate hepatic PPARα 
gene expression and activation[3]. This suggests the involvement of curtailed lipid flux 
between the liver and peripheral tissues due to excess hepatic PPARα activation in neopterin-
related atherogenesis.  Lowering of LDL-C levels by statin-treatment has been shown to result 
in CVD reduction[2] and these findings, at first glance, may, therefore, seem discordant with 
the current analysis. We do not know the initial lipid levels of these patients as the majority 
were already treated with statins at the time of angiography; however, cardiovascular events 
are common even in subjects attaining low LDL-C concentrations[4]. Although it is difficult 
to draw firm conclusions about particular mechanisms based on one study alone, our findings 
may, however, provide some insight into the residual CVD risk despite treatment with lipid-
lowering statins[4]. 
 
Strengths and limitations 
The strengths of our study include the large and well-characterized sample and its prospective 





There are limitations to our study. First, the follow-up was ascertained from the patient 
administrative data; hence, we cannot rule out some underreporting or other misclassification 
of clinical endpoints. However, we find it unlikely that such misclassification differs 
according to levels of plasma neopterin or serum lipid parameters. Second, some factors were 
not assessed, especially malnutrition which can potentially influence the levels of lipids [27]. 
However, we do not suspect any confounding role of nutrition because adjusting for serum 
albumin, a sensitive marker of undernutrition[27], and CRP, a measure of systemic 
inflammation[27], the interactions remained unchanged. Fourth, high neopterin production is 
associated with increased oxidative stress[5]. Intriguingly, despite the occurrence of oxidative 
stress in smokers[1], we observed an inverse association between plasma neopterin and 
smoking status. This finding is in line with a previous report[28] and the relationship may be 
explained by the fact that tobacco smoke has been suggested to attenuate the human immune 
system via suppressing T-helper–type 1 lymphocytes[29]. Third, nearly 46% of the patients 
received treatments with folic acid plus vitamin B12 or B6, and thus our results may not be 
generalizable to untreated populations. However, supplementation with B-vitamins is reported 
to have no significant effects on plasma neopterin levels [30]. Moreover, interactions 
persisted after adjusting for B-vitamin treatment.  Finally, the mechanism detailed in our 
study are purely speculative, and additional investigations are thus needed to better explore 
the role of low lipid measures and statin therapy in neopterin-related atherogenesis.   
Conclusion 
In patients with suspected SAP, the increased risk of AMI associated with elevated neopterin 
levels was predominately present in patients with high serum Vit-A, and those with low 
circulating LDL-C or apoB100 levels, in particular among whom receiving statin therapy 





serum LDL-cholesterol and apoB100 may share some common pathophysiological 
mechanisms that contribute to the pathogenesis of atherosclerotic CVD, which might include 
impaired hepatic VLDL-C output. Our findings motivate further investigations on the 
relationship between lipid metabolism and cellular immune activation, and atherothrombosis.  
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Figure 1. The risk association between log-transformed neopterin and acute myocardial 
infarction in subgroups of serum LDL-C levels, adjusted for age and sex. Shaded areas 
around the curves depict 95% CI. Kernel density plots show the distribution of plasma 




Figure 2. The age and sex adjusted risk association between log-transformed neopterin 
and acute myocardial infarction according to subgroups of apoB100 levels. Shaded areas 
around the curves depict 95% CI. Kernel density plots are superimposed along the x-axis, to 
display the distribution of plasma neopterin. apoB100 indicates apolipoprotein B100 
 
 
 
 
